$TRML News
Last published 1y ago
- 1y agoTRMLTourmaline Bio Enters into Agreement to be Acquired by Novartis AGGlobeNewswire– Novartis to acquire Tourmaline Bio for $48.00 per share in cash for a total equity value of approximately $1.4 billion – – Transaction reflects the potential of Tourmaline's pacibekitug, a long-acting, fully-human,
- 1y agoTRMLNovartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)GlobeNewswireTourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular diseasePacibekitug is a promising targeted therapy with
- 1y agoTRMLTourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology CongressGlobeNewswire– Poster presentation highlights the consistency of reductions in high-sensitivity C-reactive protein with pacibekitug across clinically-meaningful subgroups – – Pacibekitug demonstrated concordant, statistically
- 1y agoTRMLTourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business HighlightsGlobeNewswire– Reported positive topline results from the ongoing Phase 2 TRANQUILITY trial of pacibekitug in May 2025, demonstrating rapid, deep, and durable reductions in high-sensitivity C-reactive protein with quarterly dosing –
- 1y agoTRMLTourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney DiseaseGlobeNewswire– Rapid, deep, and durable reductions in high-sensitivity C-reactive protein (hs-CRP) through Day 90 achieved across all pacibekitug arms with high statistical significance as compared to placebo (p<0.0001 for all
- 1y agoTRMLTourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025GlobeNewswireNEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients
- 1y agoTRMLTourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business HighlightsGlobeNewswire– Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease remains on track for topline data readout in the second quarter 2025 – – Tourmaline expects to
- 1y agoTRMLTourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business HighlightsGlobeNewswire– Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease over-enrolled to 143 total participants, on track to report topline data in the second quarter of 2025
- 1y agoTRMLTourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025GlobeNewswireNEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of
- 1y agoTRMLTourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotech ConferenceGlobeNewswireNEW YORK, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients
- 1y agoTRMLTourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. RidkerGlobeNewswireNEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients
- 1y agoTRMLTourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor DayGlobeNewswire– Phase 2 TRANQUILITY trial surpasses enrollment target, with 143 total patients enrolled; topline data expected in second quarter of 2025 – – Deepak L. Bhatt, MD, MPH, MBA and Dipender Gill, MD, PhD join Cardiovascular
- 1y agoTRMLTourmaline Bio to Host Investor Day on Tuesday, December 10, 2024GlobeNewswireNEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients
- 2y agoTRMLTourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business HighlightsGlobeNewswire– On track to report topline data from Phase 2 TRANQUILITY trial in first half of 2025 – – Assembled Cardiovascular Scientific Advisory Board (CV SAB), comprised of leading academic and industry
- 2y agoTRMLTourmaline Bio to Present at Upcoming Investor ConferencesGlobeNewswireNEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients
- 2y agoTRMLTourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024GlobeNewswireNEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients
- 2y agoTRMLTourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health CongressGlobeNewswireNEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients
- 2y agoTRMLTourmaline Bio Announces Formation of Cardiovascular Scientific Advisory BoardGlobeNewswire– Tourmaline assembles leading experts to support the development of pacibekitug for cardiovascular diseases – – Cardiovascular Scientific Advisory Board expected to provide strategic guidance as Tourmaline
- 2y agoTRMLTourmaline Bio to Present at Upcoming Investor ConferencesGlobeNewswireNEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of
- 2y agoTRMLTourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business HighlightsGlobeNewswire– First patient dosed in May 2024 in Phase 2 TRANQUILITY trial evaluating pacibekitug (TOUR006) in patients with high cardiovascular risk – – On track to initiate a pivotal Phase 3 trial evaluating pacibekitug
- 2y agoTRMLTourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024GlobeNewswirePhase 2 TRANQUILITY trial is evaluating the high-sensitivity C-reactive protein (hs-CRP)-lowering effect, safety, tolerability, and pharmacokinetics (PK) of quarterly and monthly subcutaneous administration of TOUR006 in
- 2y agoTRMLTourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial OfficerGlobeNewswireNEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients
- 2y agoTRMLTourmaline Bio to Present at the Jefferies Global Healthcare ConferenceGlobeNewswireNEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients
- 2y agoTRMLTourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY TrialGlobeNewswire– First patient dosed in trial to evaluate the safety, pharmacokinetics and pharmacodynamics of TOUR006 in patients with inflammatory risk and chronic kidney disease – – Topline data anticipated in the first half of
- 2y agoTRMLTourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business HighlightsGlobeNewswire– Initiated Phase 2 TRANQUILITY trial in April 2024 following U.S. FDA clearance of Investigational New Drug application (IND) for clinical development program in Atherosclerotic Cardiovascular Disease (ASCVD) – –
- 2y agoAVTXTRMLAvalo Therapeutics Appoints Biotech Leaders to Board of DirectorsGlobeNewswireAppointments include industry veterans Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent DirectorsBoard of Director appointments in conjunction with Avalo's recent acquisition of AVTX-009, an anti-IL-1β
- 2y agoTRMLNBITourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsGlobeNewswire– Initiated pivotal spiriTED Phase 2b trial in Thyroid Eye Disease (TED) in 2023 and expanded TED clinical development plan, including accelerating the planned initiation of a pivotal Phase 3 trial into 2024 – – Reached
- 2y agoTRMLTourmaline Bio to Present at Upcoming Investor ConferencesGlobeNewswireNEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients
- 2y agoTRMLTourmaline Bio to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology ConferenceGlobeNewswireNEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients
- 2y agoTRMLTourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters' Option to Purchase Additional SharesGlobeNewswireNEW YORK, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. ("Tourmaline") (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of
- 2y agoTRMLTourmaline Bio Announces Pricing of Public Offering of Common StockGlobeNewswireNEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. ("Tourmaline") (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of
- 2y agoTRMLTourmaline Bio Announces Proposed Public Offering of Common StockGlobeNewswireNEW YORK, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. ("Tourmaline") (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of
- 2y agoTRMLTourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD)GlobeNewswireTourmaline plans to accelerate the initiation of a pivotal Phase 3 trial in 2024 evaluating subcutaneous TOUR006 every 8 weeks as first-line treatment for TED, with topline data expected in 2026 Alignment has been
- 2y agoTRMLNBITourmaline Bio added to the NASDAQ Biotechnology IndexGlobeNewswireNEW YORK, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. ("Tourmaline") (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of
- 2y agoTRMLTourmaline Bio Appoints Dr. Clay Siegall as Chairman of the BoardGlobeNewswireNEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. ("Tourmaline") (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of
- 3y agoTRMLTourmaline Bio to Present at Upcoming Investor ConferencesGlobeNewswireNEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with
- 3y agoTRMLTourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 MillionGlobeNewswireTourmaline will be focused on advancing TOUR006, its differentiated anti-IL-6 antibody, to treat thyroid eye disease (TED), atherosclerotic cardiovascular disease (ASCVD) and other diseases Post-transaction cash, cash